paclitaxel has been researched along with Constriction, Pathological in 184 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.54) | 18.2507 |
| 2000's | 26 (14.13) | 29.6817 |
| 2010's | 102 (55.43) | 24.3611 |
| 2020's | 55 (29.89) | 2.80 |
| Authors | Studies |
|---|---|
| Garvey, DS; Janero, DR; Letts, LG; Lin, CE; Marek, P; Richardson, SK; Serebryanik, D; Shumway, MJ; Tam, SW; Trocha, AM; Young, DV | 1 |
| Altevogt, F; Byrne, RA; Cassese, S; Colleran, R; Joner, M; Kastrati, A; Kufner, S; Pyxaras, S; Rai, H; Schunkert, H; Wiebe, J; Xhepa, E; Zrenner, B | 1 |
| Bi, W; Fu, W; Guo, P; Guo, W; Jia, S; Jia, X; Liu, J; Sun, G; Wang, F; Wang, S; Wu, D; Zhang, J; Zhao, Y; Zhuang, B | 1 |
| Chan, SXJM; Chandramohan, S; Chong, TT; Chua, JME; Da Zhuang, K; Damodharan, K; Gogna, A; Irani, FG; Leong, S; Lo, RHG; Patel, A; Rahman, ASBA; Sulaiman, MSB; Tan, BS; Tan, CS; Tan, Z; Tay, KH; Too, CW; Urlings, T; Venkatanarasimha, N; Win, HH | 1 |
| Kallidonis, P; Karnabatidis, D; Katsanos, C; Kitrou, P; Liatsikos, E; Liourdi, D; Papadimatos, P; Spiliopoulos, S; Tsaturyan, A | 1 |
| Barco, S; Engelberger, RP; Grigorean, A; Held, U; Holy, E; Kucher, N; Leeger, C; Münger, M; Périard, D; Probst, E; Sebastian, T; Spescha, R; Voci, D | 1 |
| Geisler, BP; Lookstein, RA; Lyden, SP; Manda, B; Misra, S; Pflederer, TA; Pietzsch, JB | 1 |
| Armstrong, EJ; Giannopoulos, S; Schneider, PA; Secemsky, EA | 1 |
| Cui, F; Huang, F; Wei, F | 1 |
| Cao, G; He, Q; Kang, H; Yu, H | 1 |
| Bugurov, SV; Cheban, AV; Gostev, AA; Ignatenko, PV; Karpenko, AA; Osipova, OS; Rabtsun, AA; Saaya, SB | 1 |
| Cao, KN; Choi, H; Chun, HJ; Haruguchi, H; Holden, A; Pietzsch, JB; Yoshikawa, M | 1 |
| Abdul Kader, MASK; Abidin, IZ; Gori, T; Jeger, R; Liew, HB; Mahfoud, F; Mangner, N; Mohd Ali, R; Nuruddin, AA; Ong, TK; Scheller, B; Schnorr, B; Schwenke, C; Wan Ahmad, WA; Wöhrle, J; Woitek, F | 1 |
| Ando, K; Brodmann, M; Doros, G; Farhan, S; Iida, O; Kamran, H; Krishnan, P; Laird, J; Micari, A; Sachar, R; Scheinert, D; Schneider, P; Tarricone, A; Tepe, G; Urasawa, K; Yokoi, H; Zeller, T | 1 |
| Koyama, A; Morishima, I; Morita, Y; Nishikawa, R; Shimamura, K; Tokuda, T; Yamada, T; Yoshioka, N | 1 |
| Chen, P; He, B; Hu, Q; Jia, J; Qin, H; Shen, Z; Tao, Y; Yang, R; Yu, M; Yu, Z; Zhang, L | 1 |
| Alfonso, F; Brugaletta, S; Escaned, J; Fernández-Ortiz, A; Gonzalo, N; Jerónimo-Baza, A; Jimenez-Quevedo, P; Jiménez-Valero, S; Macaya, C; McInerney, A; Nombela-Franco, L; Pérez-Vizcayno, MJ; Romaguera, R; Salazar, C; Tirado-Conte, G; Travieso-Gonzalez, A | 1 |
| Beschorner, U; Blessing, E; Brechtel, K; Brucks, S; Euringer, W; Langhoff, R; Maiwald, L; Popescu, C; Scheinert, D; Schellong, S; Schmidt, A; Schröder, H; Schuster, J; Steiner, S; Tepe, G; Thieme, M; Weiss, N; Wittig, T; Zeller, T | 1 |
| Bettink, S; Bienek, S; Brunacci, N; Gemeinhardt, O; Haase, T; Kelsch, B; Löchel, M; Scheller, B; Schnorr, B; Schütt, D; Speck, U | 1 |
| Bettink, S; Bienek, S; Gemeinhardt, O; Kusmierczuk, M; Scheller, B; Schnorr, B | 1 |
| Chen, X; Dong, H; Fu, W; Huang, X; Jiang, W; Li, X; Lu, X; Wang, H; Yang, J; Yue, J | 1 |
| Almeida, RS; Alvim Fiorelli, RK; Belczac, SQ; Dalio, MB; Gutfilen, B; Joviliano, EE; Oliveira, R; Peclat de Oliveira, JC; Peclat de Oliveira, LM; Rolim Maia Peclat, AP | 1 |
| Heller, MB; Lam, A; Wu, X; Youm, J; Zhou, AL | 1 |
| Alfonso, F; Cuculi, F; Díaz, VAJ; Gaede, L; Leibundgut, G; Nuruddin, AA; Otto, S; Pyxaras, S; Rittger, H; Rosenberg, M; Schulze, C; Steen, P; Waliszewski, MW; Wan Ahmad, WA; Weilenmann, D; Wöhrle, J | 1 |
| Aoki, H; Hisauchi, I; Ishikawa, T; Itabashi, Y; Kobayashi, S; Kondo, Y; Mizutani, Y; Nakahara, S; Nakamura, H; Shimura, M; Taguchi, I; Ukaji, T; Yamada, K | 1 |
| Chen, H; Fu, G; Li, H; Li, W; Li, Z; Liu, S; Qiao, S; Qiu, C; Shen, Z; Yu, Z; Zeng, Q; Zhou, Y | 1 |
| Fujita, T; Haraguchi, T; Kashima, Y; Otake, R; Sato, K; Tsujimoto, M | 1 |
| Boon, JC; Chen, TY; Hsieh, MY; Liao, MT; Lin, L; Lin, PS; Wu, CC; Yang, TF | 1 |
| Alfonso, F; Byrne, RA; Copt, S; Cortese, B; Fitzgerald, S; Hahn, JY; Morice, MC; Mylotte, D; O'Kane, P; Oldroyd, KG; Rai, H; Sabaté, M; Schuette, D; Tölg, R; Traynor, BP; Trevelyan, J; Wöhrle, J | 1 |
| Da Zhuang, K; Gogna, A; Irani, FG; Tan, BS; Tay, KH; Too, CW | 1 |
| Hu, XY; Li, ZG; Wang, QB; Yuan, FL; Zhang, Y; Zou, ZW | 1 |
| Aihara, K; Ikari, Y; Kato, T; Nakamura, N; Nakazawa, G; Nakazawa, K; Noda, S; Torii, S | 1 |
| Rissanen, TT | 1 |
| Gad, MM; Karrthik, AK; Mahmoud, AA; Mahmoud, AN | 1 |
| García-Revillo, J; Machancoses, FH; Moreno-Ramírez, M; Moreno-Sánchez, T; Navarro-Vergara, PF; Pardo-Moreno, P | 1 |
| Alvandi, B; Armstrong, EJ; Behan, S; Foley, TR; Giannopoulos, S; Hossain, P; Jawaid, O; Kokkinidis, DG; Singh, GD; Waldo, SW | 1 |
| Ang, HY; Chaw, SY; Chong, TT; Huang, Y; Ng, JCK; Phua, JL; Venkatraman, S; Wong, PEH; Xiong, GM | 1 |
| Behrendt, CA; Bertges, DJ; Debus, ES; Kölbel, T; Kreutzburg, T; L'Hoest, H; Larena-Avellaneda, A; Peters, F; Schermerhorn, M; Sedrakyan, A | 1 |
| Gruber, P; Remonda, L | 1 |
| Babaev, A; Bachinsky, W; Diaz-Cartelle, J; Golzar, J; Gray, WA; Iida, O; Kawasaki, D; Müller-Hülsbeck, S; Park, J; Prem, JT; Soga, Y; Vermassen, F | 1 |
| Fang, L; Lai, Z; Lei, J; Li, K; Liu, B; Liu, X; Shao, J; Wang, J; Xu, L; Yu, X; Zhang, X | 1 |
| Han, J; Meng, Y; Song, Y; Sun, L; Wang, W; Yin, H; Zhang, J; Zhang, X; Zhao, W; Zheng, M | 1 |
| Gomes, ML; Katib, N; Narroway, HG; Thomas, SD; Varcoe, RL | 1 |
| Benko, A; Brodmann, M; Choi, D; Dobranszki, R; Guo, J; Jaff, MR; Micari, A; Stavroulakis, K; Tepe, G; Torsello, G; Vermassen, FEG; Veroux, P; Zeller, T | 1 |
| Byun, SS; Kang, JM; Kim, JH; Kim, JW; Shin, JH | 1 |
| Cihlar, S; Haruguchi, H; Holden, A; Lei, L; Lookstein, RA; Ouriel, K; Weinberg, I | 1 |
| Asada, H; Fujiwara, R; Higuchi, K; Isawa, K; Kijima, Y; Kozuki, A; Miyata, T; Nagoshi, R; Sakamoto, Y; Seo, H; Shibata, H; Shimizu, M; Shite, J; Soga, F; Suzuki, A; Takahara, M | 1 |
| Annapureddy, A; Aronow, HD; Curtis, JP; Jelani, QU; Jones, WS; Mena-Hurtado, C; Patel, MR; Secemsky, EA; Shishehbor, MH; Tsai, TT; Wang, Y; Weissler, EH | 1 |
| Jonczy, ML; Thalhammer, C | 1 |
| Chen, J; Cui, T; Jin, Q; Li, H; Shi, Y; Wu, K; Yan, Y; Yin, Y; Yu, Z; Zhang, L | 1 |
| Bisdas, T; Cancellieri, R; Coscas, R; El Hage, R; Jaffer, O; Karnabatidis, D; Katsanos, K; Kitrou, PM; Lucatelli, P; Mallios, A; Ponce, P; Spiliopoulos, S; Spinelli, A; Stavroulakis, K; Steinke, T; Zilahi de Gyurgyokai, S | 1 |
| Cakir, S; Guzelbey, T; Kilickesmez, O; Mutlu, IN | 1 |
| Bajardi, G; Dinoto, E; Ferlito, F; Mirabella, D; Pakeliani, D; Pecoraro, F | 1 |
| Antoniou, GA; Argyriou, C; Christaina, E; Georgiadis, GS; Lazarides, MK; Trypsianis, G | 1 |
| Barnhill, S; Chan, SL; Chong, TT; DeGraw, RT; Finn, AV; Hellinga, D; Soon, SXY; Tan, CS; Tan, RY; Tang, TY; Tay, HT; Yap, CJQ; Yap, HY | 1 |
| Pang, SC; Tan, CS; Tan, RY; Tng, ARK | 1 |
| Beelen, R; Bosiers, M; Callaert, J; Deloose, K; Hendriks, JMH; Keirse, K; Maene, L; Peeters, P; Verbist, J | 1 |
| Burrows, SA; Daneshmand, A; Daniel, R; Mwipatayi, BP; Perera, K; Thomas, SD; Wong, J | 1 |
| Chang, G; Li, Z; Wang, M; Wang, S; Wu, R; Yao, C | 1 |
| Cheng, Y; Conditt, GB; Gasior, P; Granada, JF; Kaluza, GL; McGregor, J; Valencia, AF | 1 |
| Bunch, F; Carr, J; Kassab, E; Walker, C | 1 |
| Cassese, S; Dewitz, K; Fusaro, M; Groha, P; Hadamitzky, M; Ibrahim, T; Kasel, AM; Kastrati, A; Kufner, S; Laugwitz, KL; Ott, I; Schunkert, H; Steppich, B; Voll, F; Wittmann, T | 1 |
| Duda, S; Lux, B; Martorana, M; Meyer, DR; Miller, LE; Ruecker, F; Schroeder, H | 1 |
| Brodmann, M; Jaff, MR; Keirse, K; Li, P; Scheinert, D; Schmahl, R; Spak, L; Zeller, T | 1 |
| Chisci, E; Frosini, P; Guidotti, A; Michelagnoli, S; Romano, E; Troisi, N | 1 |
| Barbalias, D; Kallidonis, P; Kyriazis, I; Lappas, G; Liatsikos, E; Liourdi, D; Ravazoula, P | 1 |
| Breznik, S; Dinevski, D; Ekart, R; Lučev, J; Rupreht, M | 1 |
| Del Giudice, C; Diaz-Cartelle, J; Geist, V; Lichtenberg, M; Marx, C; Sauguet, A; Scheinert, D; Schult, I; Sievert, H; Steiner, S; Ströbel, A; Willfort-Ehringer, A | 1 |
| Brodmann, M; Frost, M; Keirse, K; Micari, A; Peeters, P; Tepe, G; Wang, H; Zeller, T | 1 |
| Argyriou, A; Beropoulis, E; Bisdas, T; Stavroulakis, K; Torsello, G | 1 |
| Cui, J; Irani, Z; Meiyan Qing, J; Zheng, J | 1 |
| Lawson, J; Roy-Chaudhury, P; Saad, TF; Trerotola, SO | 1 |
| Brodmann, M; Granada, JF; Jaff, MR; Krüger, K; Meyer, DR; Reimer, P; Schroeder, H; Werner, M | 1 |
| Cao, F; Chen, H; Chen, L; Chen, S; Chen, Y; Fu, G; Gao, L; Guan, C; Guo, J; Jin, Q; Jin, Z; Li, H; Li, W; Li, X; Qin, Q; Sun, Z; Wang, L; Wang, Y; Xu, B; Zhang, J; Zhang, Z; Zhao, Y; Zheng, Y | 1 |
| Buszman, PE; Buszman, PP; Dębiński, M; Gąsior, M; Granada, JF; Jelonek, M; Kachel, M; Kiesz, RS; Ludyga, T; Milewski, K; Nowakowski, P; Orlik, B; Polczyk, F; Żurakowski, A | 1 |
| Broughton, A; Fourneau, I; Ghijselings, L; Leclef, Y; Provoost, A; Reginster, F; Van Calster, K; Yazar, O | 1 |
| Honton, B; Philippart, R; Sauguet, A | 1 |
| Chervenkoff, V; Esposito, G; Gerardi, D; Giugliano, G; Goverde, P; Kotasov, D; Magliulo, F; Stabile, E; Taeymans, K; Trimarco, B; Zhelev, D | 1 |
| Jaff, MR; Keirse, K; Li, P; Micari, A; Scheinert, D; Schmahl, R; Tepe, G; Zeller, T | 1 |
| Cheng, Y; Cui, W; Deng, L; Fang, T; Hu, N; Li, M; Wang, J; Xiao, J; Zhang, Y; Zhu, Y | 1 |
| Adachi, A; Bolstad, F; Fujimura, N; Ichihashi, S; Iwakoshi, S; Kichikawa, K; Kyuragi, R; Nagatomi, S; Obayashi, K; Saeki, K; Shibata, T; Yamamoto, H | 1 |
| Beschorner, U; Brechtel, K; Dake, MD; Kultgen, PL; Noory, E; Rastan, A; Tepe, G; Zeller, T | 1 |
| Biamino, G; Castriota, F; Cioppa, A; Cremonesi, A; Grattoni, C; Liso, A; Marchese, A; Micari, A; Pantaleo, P; Rubino, P; Vadalà, G | 2 |
| de Boer, SW; de Vries, JP; Elgersma, O; Fioole, B; Heyligers, JM; Karimi, A; Lohle, PN; Nolthenius, RP; van den Heuvel, DA; Vos, JA; Vroegindeweij, D | 1 |
| Byrne, RA; Cassese, S; Fusaro, M | 1 |
| Chang, J; Chen, NW; Cheng, YS; Cui, WG; Yan, L; Zhu, YQ | 1 |
| Afari, M; Buszman, PP; Cheng, Y; Conditt, GB; Granada, JF; Kaluza, GL; McGregor, JC; Milewski, K; Stenoien, M; Tellez, A | 1 |
| Afari, ME; Buszman, PP; Conditt, GB; Granada, JF; Kaluza, GL; McGregor, JC; Peppas, A; Rousselle, SD; Stenoien, M; Tellez, A | 1 |
| Airoldi, F; Baldino, G; Clerici, G; Faglia, E; Gori, A; Latib, A; Losa, S; Mortola, P; Tavano, D | 1 |
| Angioli, P; Bellandi, G; Bolognese, L; Ducci, K; Falsini, G; Grotti, S; Liistro, F; Porto, I; Ricci, L; Turini, F; Ventoruzzo, G | 3 |
| Beschorner, U; Brechtel, K; Claussen, CD; Scheller, B; Schnorr, B; Speck, U; Tepe, G; Zeller, T | 1 |
| Diehm, N; Schneider, H | 1 |
| Cho, H; Fujikawa, H; Iwasaki, K; Kasahara, A; Masuda, M; Ogata, T; Osaragi, T; Rino, Y; Shirai, J; Sujishi, K; Tsuburaya, A; Yamada, T; Yamamoto, Y; Yoneyama, K; Yoshikawa, T | 1 |
| Bosiers, M; Duda, S; Krankenberg, H; Naisbitt, S; Ricke, J; Rosenfield, K; Scheinert, D; Tepe, G; Zeller, T | 1 |
| Baek, I; Hwang, J; Kim, DJ; Kim, H; Park, J; Park, JS | 1 |
| Biamino, G; Cioppa, A; Cota, L; Esposito, G; Giugliano, G; Popusoi, G; Pucciarelli, A; Rubino, P; Salemme, L; Stabile, E; Tesorio, T; Trimarco, B; Virga, V | 1 |
| Karunanithy, N; Katsanos, K; Krokidis, M; Sabharwal, T; Spiliopoulos, S; Taylor, P | 1 |
| Ahmed, I; Diamantopoulos, A; Karunanithy, N; Katsanos, K; Kitrou, P; Padayachee, S; Parthipun, A; Zayed, H | 1 |
| Becquemin, JP; Houbballah, R; Leopardi, M | 1 |
| Fuehner, T; Gottlieb, J; Greer, M; Haverich, A; Heilmann, T; Noack, H; Warnecke, G; Welte, T | 1 |
| Kim, M; Kim, MK; Kim, SY; Lee, DH; Lee, DK; Lee, H; Yang, SG | 1 |
| Karnabatidis, D; Katsanos, K; Kitrou, PM; Siablis, D; Spiliopoulos, S | 2 |
| Ansel, GM; Dake, MD; Jaff, MR; Kichikawa, K; Kimura, T; O'Leary, EE; Ohki, T; Ragheb, AO; Snyder, SA; Yokoi, H | 1 |
| Herten, M; Imm, B; Osada, N; Schönefeld, E; Stahlhoff, S; Torsello, GB | 1 |
| Dattilo, R; Gongora, CA; Granada, JF; Hyon, CM; Kaluza, GL; Mustapha, JA; Palmieri, T; Rousselle, S; Tellez, A | 1 |
| Fujihara, M; Higashimori, A; Nakamura, M; Utsunomiya, M; Yokoi, Y | 1 |
| Chaillou, P; Costargent, A; Fairier, D; Gestin, S; Gouëffic, Y; Guyomarch, B; Kaladji, A; Montagne, C; Patra, P; Riche, VP; Vent, PA | 1 |
| Burket, MW; Moukarbel, GV | 1 |
| Albrecht, T; Brechtel, K; Claussen, CD; Scheller, B; Schnorr, B; Speck, U; Tepe, G; Zeller, T | 1 |
| Beckebaum, S; Cicinnati, VR; Hüsing, A; Kabar, I; Reinecke, H; Schmidt, HH; Wilms, C | 1 |
| Hirano, K; Ishimori, H; Ito, Y; Mori, S; Muramatsu, T; Nakano, M; Tsukahara, R | 1 |
| Chen, NW; Cheng, YS; Cui, WG; Wang, L; Zhu, YQ | 1 |
| Pityk, AI | 1 |
| Donas, KP; Herten, M; Osada, N; Stahlhoff, S; Torsello, G | 1 |
| Barakat, AI; Belitz, P; Bewley, T; Bozsak, F; Chomaz, JM; Gonzalez-Rodriguez, D; Sternberger, Z | 1 |
| Cheng, Y; Conditt, GB; Gongora, CA; Granada, JF; Kaluza, GL; McGregor, J; Shibuya, M; Tellez, A; Wessler, JD | 1 |
| Bil, J; Gil, RJ; Grundeken, MJ; Iñigo Garcia, LA; Kern, A; Pawłowski, T; Serruys, PW; Vassilev, D; Wykrzykowska, JJ | 1 |
| Banning-Eichenseer, U; Bausback, Y; Scheinert, D; Scheinert, S; Schmidt, A; Steiner, S; Ulrich, M; Werner, M | 1 |
| Diamantopoulos, A; Karnabatidis, D; Katsanos, K; Paraskevopoulos, I; Spiliopoulos, S | 1 |
| Geng, H; Guo, J; He, C; Ji, X; Li, J; Yan, F; Yu, G; Zheng, H; Zhu, X | 1 |
| Fitzgerald, PJ; Fujii, K; Fukunaga, M; Honda, Y; Horimatsu, T; Imanaka, T; Ishihara, M; Kawasaki, D; Kimura, T; Masuyama, T; Miki, K; Nishimura, M; Okada, K; Saita, T; Shibuya, M; Sumiyoshi, A; Tamaru, H | 1 |
| Banning-Eichenseer, U; Bausback, Y; Bräunlich, S; Scheinert, D; Schmidt, A; Steiner, S; Ulrich, M | 1 |
| Ketelsen, D; Müller-Hülsbeck, S; Ricke, J; Rosenfield, K; Scheinert, D; Schmidt, A; Schröder, H; Sixt, S; Steiner, S; Weiss, N; Zeller, T | 1 |
| Karnabatidis, D; Katsanos, K; Kitrou, P | 1 |
| Castriota, F; Cesana, BM; Cremonesi, A; Grattoni, C; Liso, A; Marchese, A; Micari, A; Pantaleo, P; Roscitano, G; Russo, P; Vadalà, G | 1 |
| Diaz-Cartelle, J; Keirse, K; Müller-Hülsbeck, S; Schroë, H; Zeller, T | 1 |
| Lee, MS; Sethi, SS | 1 |
| Baker, NC; Bernardo, NL; Campia, U; Didier, RJ; Escarcega, RO; Kang, WY; Kiramijyan, S; Koifman, E; Lipinski, MJ; Negi, SI; Torguson, R; Waksman, R | 1 |
| Du, X; Guo, W; Hu, ZZ; Jia, SH; Jia, X; Liu, XP; Sun, GY; Xu, YL; Zhang, J | 1 |
| Kret, MR; Lee, JT; Tran, K; Ullery, BW | 1 |
| Carrafiello, G; Duka, E; Fontana, F; Franchin, M; Ierardi, AM; Miele, V; Piffaretti, G; Tonolini, M; Tozzi, M | 1 |
| Herten, M; Schönefeld, E; Stahlhoff, S; Torsello, GB | 1 |
| Del Giudice, C; Gandini, R | 1 |
| Aschenbach, R; Blessing, E; Brechtel, K; Lehmann, T; Lichtenberg, M; Riambau, V; Scheinert, D; Sixt, S; Teichgräber, U; Thieme, M; Treitl, M; Vogel, B; von Flotow, P; Werk, M; Wienke, A; Zeller, T | 1 |
| Balasubramanian, K; Cairns, J; Cantor, WJ; DeLarochellière, R; Dzavik, V; Graham, JJ; Jolly, SS; L'Allier, PL; Le May, MR; Mansour, S; Rodés-Cabau, J; Teefy, PJ; Wood, D | 1 |
| Beropoulis, E; Bisdas, T; Bosiers, MJ; Hericks, C; Schwindt, A; Stachmann, A; Stahlhoff, S; Stavroulakis, K; Torsello, G | 1 |
| Iida, O; Kawasaki, D; Matoba, S; Nanto, S; Soga, Y; Takahara, M; Yokoi, H; Zen, K | 1 |
| Briguori, C; Taranto, D; Visconti, G | 1 |
| de Vries, JP; Hansen, BE; Knippenberg, B; Martens, JM; van Overhagen, H; Vos, JA | 1 |
| Forbes, TL | 1 |
| Dragulescu, A; Fraisse, A; Ghez, O; Quilici, J | 1 |
| Ishibashi-Ueda, H; Ito, K; Ito, Y; Shimokawa, H; Shiroto, T; Takahashi, J; Tsuburaya, R; Yasuda, S | 1 |
| Nickenig, G; Sinning, JM | 1 |
| Anstrom, KJ; Cutlip, DE; Douglas, JS; Eisenstein, EL; Kandzari, DE; Kirtane, AJ; Leon, MB; Mauri, L; McLaurin, BT; Nikolsky, E; O'Shaughnessy, C; Overlie, PA; Popma, JJ; Solomon, SL | 1 |
| Chae, IH; Cho, YS; Choi, DJ; Chung, JW; Kang, HJ; Kim, HS; Koo, BK; Lee, HY; Oh, BH; Park, JS; Park, KW; Park, YB; Yang, HM; Youn, TJ | 1 |
| Cester, G; Manzi, M; Palena, LM | 1 |
| Gomes, M; Groffsky, JL; Leville, CD; Long, TD; McMillan, WD; Schultz, SR | 1 |
| Chun, KR; De Potter, TJ; Kuck, KH; Malisius, R; Nuyens, D; Ouyang, F; Schmidt, B; Schneider, C | 1 |
| Barry, JJ; Cheng, R; Eppihimer, MJ; Lavigne, MC | 1 |
| De Jaegere, P; Deckers, JW; Magro, M; Nauta, ST; Regar, E; Serruys, PW; Simsek, C; Van Der Giessen, WJ; Van Domburg, RT; Van Geuns, RJ; Van Mieghem, NM | 1 |
| Scheller, B; Schnorr, B; Speck, U | 1 |
| Bosiers, M; Dake, MD; Fanelli, F; Kavteladze, Z; Lottes, AE; Ragheb, AO; Ruhlmann, C; Scheinert, D; Tepe, G; Tessarek, J; Zeller, T | 1 |
| Biamino, G; Castriota, F; Cioppa, A; Cremonesi, A; Grattoni, C; Marchese, A; Micari, A; Pantaleo, P; Rubino, P; Stabile, E; Vadalà, G | 1 |
| Baek, I; Bai, CZ; Hwang, J; Kim, DJ; Park, J; Park, JS | 1 |
| Ding, F; Guo, Q; Li, S; Lu, Z; Yang, J; Zhang, Y; Zou, R | 1 |
| Christeas, N; Karnabatidis, D; Katsanos, K; Kitrou, P; Siablis, D; Spiliopoulos, S | 1 |
| Ju, MH; Rodríguez, HE | 1 |
| Minar, E; Schillinger, M | 1 |
| Boatta, E; Cannavale, A; Cirelli, C; Corona, M; Fanelli, F; Lucatelli, P; Salvatori, FM; Wlderk, A | 1 |
| Avsar, Y; Beckebaum, S; Cicinnati, VR; Cordesmeyer, S; Kabar, I; Reinecke, H; Schmidt, HH | 1 |
| Ahmed, MN; Albrecht, T; Behne, A; Dietz, U; Eschenbach, G; Hänninen, EL; Hartmann, H; Lange, C; Meyer, DR; Schnorr, B; Stiepani, H; Werk, M; Zoccai, GB | 1 |
| Garces, K | 1 |
| Nashimoto, A; Sakurai, K; Yabusaki, H | 1 |
| Aikou, T; Arima, H; Hamada, N; Hokita, S; Ishigami, S; Maeda, S; Miyazono, F; Natsugoe, S; Takao, S; Takatori, H | 1 |
| Imazu, H; Matsubara, T; Nakamura, Y; Ochiai, M; Sakai, W; Sakurai, Y; Tonomura, S; Yoshida, I | 1 |
| Claussen, CD; Duda, SH; Kehlbach, R; Schart, N; Schöber, W; Tepe, G; Wersebe, A; Wiskirchen, J | 1 |
| Cheung, AK; Kamerath, CD; Kim, SJ; Leypoldt, JK; Masaki, T; Mohammad, SF | 1 |
| Bailey, SR | 1 |
| Chijiiwa, K; Eto, TA; Hotokezaka, M; Iwamura, T; Shibata, N | 1 |
| Carneiro, F; Lima, J; Lopes, JM; Magro, F; Pereira, P; Saraiva, A; Sarmento, C; Tavarela-Veloso, F; Teixeira, A | 1 |
| Betge, S; Figulla, HR; Fritzenwanger, M; Krack, A; Prochnau, D; Schwarz, G; Werner, GS | 1 |
| Konner, K | 1 |
| Han, YL; Jing, QM; Luan, B; Ma, YY; Wang, SL; Wang, XZ | 1 |
| Kanamaru, T; Tanaka, K; Yamamoto, M | 1 |
| Bakowsky, U; Fuchs, J; Kalinowski, M; Kissel, T; Merdan, T; Schäller, S; Unger, F; Westedt, U; Wittmar, M | 1 |
| Jeon, HJ; Kim, DJ; Kim, JS; Ko, JY; Lee, BH; Lee, JE; Lee, KW; Lim, HJ; Nam, HY; Park, JS; Sung, YJ | 1 |
| Albrecht, T; Baier, C; Böhm, M; Scheller, B; Speck, U; Wolf, KJ | 1 |
| Ahn, Y; Cho, JG; Hong, SN; Hong, YJ; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Kim, W; Lee, SR; Park, HW; Park, JC | 1 |
| Mayo, DJ | 1 |
| Axel, DI; Baumbach, A; Blattner, A; Heinle, H; Herdeg, C; Karsch, KR; Oberhoff, M; Schröder, S | 1 |
20 review(s) available for paclitaxel and Constriction, Pathological
| Article | Year |
|---|---|
The Role of Drug-Coated Balloon in Haemodialysis Arteriovenous Fistula Stenosis Management.
Topics: Angioplasty, Balloon; Arteriovenous Fistula; Arteriovenous Shunt, Surgical; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Graft Occlusion, Vascular; Humans; Hyperplasia; Paclitaxel; Renal Dialysis; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2023 |
Comparison of drug-coated balloon angioplasty versus common balloon angioplasty for arteriovenous fistula stenosis: A systematic review and meta-analysis.
Topics: Angioplasty, Balloon; Arteriovenous Fistula; Coated Materials, Biocompatible; Constriction, Pathologic; Graft Occlusion, Vascular; Humans; Paclitaxel; Time Factors; Treatment Outcome; Vascular Patency | 2023 |
Is There a Safety Concern for Drug-Coated Balloons in Peripheral Arterial Disease?
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Drug-Eluting Stents; Endovascular Procedures; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Treatment Outcome | 2019 |
Device profile of different paclitaxel-coated balloons: Neuro Elutax SV, Elutax '3' Neuro and SeQuent Please NEO for the treatment of symptomatic intracranial high-grade stenosis: overview of their feasibility and safety.
Topics: Angioplasty, Balloon; Atherosclerosis; Coated Materials, Biocompatible; Constriction, Pathologic; Feasibility Studies; Humans; Paclitaxel | 2020 |
Plain versus paclitaxel-coated balloon angioplasty in arteriovenous fistula and graft stenosis: An umbrella review.
Topics: Angioplasty, Balloon; Arteriovenous Fistula; Arteriovenous Shunt, Surgical; Coated Materials, Biocompatible; Constriction, Pathologic; Humans; Paclitaxel; Renal Dialysis; Treatment Outcome; Vascular Patency | 2022 |
Paclitaxel-coated versus uncoated balloon angioplasty for femoropopliteal artery in-stent restenosis.
Topics: Angioplasty, Balloon; Constriction, Pathologic; Femoral Artery; Humans; Paclitaxel; Popliteal Artery; Prospective Studies; Stents | 2017 |
Directional atherectomy with antirestenotic therapy for the treatment of no-stenting zones.
Topics: Angioplasty, Balloon; Atherectomy; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Humans; Paclitaxel; Peripheral Arterial Disease; Recurrence; Risk Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2019 |
Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery.
Topics: Alloys; Amputation, Surgical; Angioplasty, Balloon; Bayes Theorem; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Drug-Eluting Stents; Equipment Design; Femoral Artery; Humans; Limb Salvage; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Sirolimus; Stents; Treatment Outcome; Vascular Access Devices | 2014 |
Paclitaxel-eluting stents for the treatment of femoropopliteal arterial stenoses: focus on the Zilver PTX drug-eluting peripheral stent.
Topics: Clinical Trials as Topic; Constriction, Pathologic; Drug-Eluting Stents; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery | 2015 |
Systematic Review and Meta-analysis of Randomized Controlled Trials of Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Arteries: Role of Paclitaxel Dose and Bioavailability.
Topics: Amputation, Surgical; Angioplasty, Balloon; Biological Availability; Cardiovascular Agents; Chi-Square Distribution; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Femoral Artery; Humans; Limb Salvage; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2016 |
Drug-coated balloons are replacing the need for nitinol stents in the superficial femoral artery.
Topics: Alloys; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Cost-Benefit Analysis; Female; Femoral Artery; Health Care Costs; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prosthesis Design; Stents; Treatment Outcome; Vascular Access Devices | 2016 |
Drug-Coated Balloons for Infrainguinal Peripheral Artery Disease.
Topics: Angioplasty; Antineoplastic Agents, Phytogenic; Coated Materials, Biocompatible; Constriction, Pathologic; Drug-Eluting Stents; Femoral Artery; Humans; Hyperplasia; Long Term Adverse Effects; Neointima; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Vascular Patency | 2016 |
Critical appraisal of paclitaxel balloon angioplasty for femoral-popliteal arterial disease.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Critical Illness; Equipment Design; Femoral Artery; Humans; Ischemia; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2016 |
Paclitaxel-coated balloon angioplasty for lower extremity revascularization: a new way to fight in-stent restenosis.
Topics: Angioplasty, Balloon; Animals; Arterial Occlusive Diseases; Cardiovascular Agents; Constriction, Pathologic; Drug-Eluting Stents; Evidence-Based Medicine; Humans; Lower Extremity; Paclitaxel; Prosthesis Design; Secondary Prevention; Treatment Outcome | 2010 |
Anti-proliferative compounds for the prevention of restenosis.
Topics: Cell Proliferation; Constriction, Pathologic; Coronary Artery Disease; Humans; Paclitaxel; Stents | 2010 |
Review of clinical data with Paccocath- coated balloon catheters.
Topics: Arterial Occlusive Diseases; Catheterization; Constriction, Pathologic; Coronary Stenosis; Equipment Design; Humans; Paclitaxel | 2011 |
Standard balloon angioplasty versus angioplasty with paclitaxel-eluting balloons for femoropopliteal artery stenosis.
Topics: Angioplasty, Balloon; Animals; Arterial Occlusive Diseases; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Drug-Eluting Stents; Femoral Artery; Humans; Paclitaxel; Popliteal Artery; Treatment Outcome | 2012 |
Innovative technologies for SFA occlusions: drug coated balloons in SFA lesions.
Topics: Angioplasty, Balloon; Animals; Arterial Occlusive Diseases; Cardiovascular Agents; Catheters; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Radiography; Recurrence; Treatment Outcome; Vascular Patency | 2012 |
Drug-eluting stents have made brachytherapy obsolete.
Topics: Angioplasty, Balloon, Coronary; Brachytherapy; Constriction, Pathologic; Humans; Paclitaxel; Sirolimus; Stents | 2004 |
Fibrin sheath formation and chemotherapy extravasation: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catheterization, Central Venous; Catheters, Indwelling; Constriction, Pathologic; Cyclophosphamide; Equipment Failure; Extravasation of Diagnostic and Therapeutic Materials; Female; Fibrin; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Plasminogen Activators; Urokinase-Type Plasminogen Activator | 1998 |
47 trial(s) available for paclitaxel and Constriction, Pathological
| Article | Year |
|---|---|
A prospective trial of a novel low-dose paclitaxel-coated balloon therapy in patients with restenosis in drug-eluting coronary stents Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-stent REstenosis 3A (ISAR-
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Constriction, Pathologic; Coronary Angiography; Coronary Restenosis; Drug-Eluting Stents; Humans; Middle Aged; Paclitaxel; Prospective Studies; Stents; Treatment Outcome | 2022 |
Major adverse limb events in patients with femoro-popliteal and below-the-knee peripheral arterial disease treated with either sirolimus-coated balloon or standard uncoated balloon angioplasty: a structured protocol summary of the "SirPAD" randomized cont
Topics: Angioplasty, Balloon; Clinical Trials, Phase III as Topic; Coated Materials, Biocompatible; Constriction, Pathologic; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Randomized Controlled Trials as Topic; Sirolimus; Treatment Outcome; Vascular Patency | 2022 |
IN.PACT AV Access Trial: Economic Evaluation of Drug-Coated Balloon Treatment for Dysfunctional Arteriovenous Fistulae Based on 12-Month Clinical Outcomes.
Topics: Aged; Angioplasty, Balloon; Arteriovenous Fistula; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Cost-Benefit Analysis; Femoral Artery; Humans; Medicare; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Time Factors; Treatment Outcome; United States; Vascular Patency | 2022 |
One-Year Results of Long femoropopliteal Lesions Stenting with Fasciotomy Lamina Vastoadductoria.
Topics: Constriction, Pathologic; Fasciotomy; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Stents; Treatment Outcome; Vascular Patency | 2023 |
Economics of drug-coated balloons for arteriovenous fistula stenosis in Japan and Korea based on the IN.PACT AV access trial.
Topics: Angioplasty, Balloon; Arteriovenous Fistula; Arteriovenous Shunt, Surgical; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Humans; Japan; Paclitaxel; Renal Dialysis; Time Factors; Treatment Outcome; Vascular Patency | 2022 |
Low-Dose vs High-Dose Paclitaxel-Coated Balloons for Femoropopliteal Lesions: 2-Year Results From the COMPARE Trial.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Pilot Projects; Polychlorinated Biphenyls; Popliteal Artery; Prospective Studies; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2022 |
A Randomized Comparison of 2 Different Drug-Coated Balloons for In-Stent Restenosis.
Topics: Angioplasty, Balloon, Coronary; Cardiac Catheters; Coated Materials, Biocompatible; Constriction, Pathologic; Coronary Angiography; Coronary Restenosis; Drug-Eluting Stents; Humans; Paclitaxel; Prospective Studies; Treatment Outcome | 2023 |
A Randomised Trial Comparing Drug Coated Balloons and Conventional Balloons for the Treatment of Stent Graft Stenosis in Dialysis Vascular Access.
Topics: Angioplasty, Balloon; Arteriovenous Shunt, Surgical; Coated Materials, Biocompatible; Constriction, Pathologic; Humans; Paclitaxel; Prospective Studies; Renal Dialysis; Stents; Treatment Outcome; Vascular Patency | 2023 |
Design and rationale of a prospective, randomized, non-inferiority trial to determine the safety and efficacy of the Biolimus A9™ drug coated balloon for the treatment of in-stent restenosis: First-in-man trial (REFORM).
Topics: Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Coronary Angiography; Coronary Restenosis; Drug-Eluting Stents; Humans; Paclitaxel; Pharmaceutical Preparations; Prospective Studies; Single-Blind Method; Sirolimus; Treatment Outcome | 2023 |
Efficacy of Paclitaxel Balloon for Hemodialysis Stenosis Fistulae After One Year Compared to High-Pressure Balloons: A Controlled, Multicenter, Randomized Trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Arteriovenous Shunt, Surgical; Constriction, Pathologic; Female; Fistula; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Renal Dialysis; Treatment Outcome; Tubulin Modulators; Vascular Patency | 2020 |
Effectiveness and Safety of a Paclitaxel-Eluting Stent for Superficial Femoral Artery Lesions up to 190 mm: One-Year Outcomes of the Single-Arm IMPERIAL Long Lesion Substudy of the Eluvia Drug-Eluting Stent.
Topics: Aged; Amputation, Surgical; Cardiovascular Agents; Constriction, Pathologic; Drug-Eluting Stents; Endovascular Procedures; Europe; Female; Femoral Artery; Humans; Japan; Limb Salvage; Male; Middle Aged; New Zealand; Paclitaxel; Patient Safety; Peripheral Arterial Disease; Progression-Free Survival; Prospective Studies; Prosthesis Design; Risk Assessment; Risk Factors; Time Factors; United States; Vascular Calcification; Vascular Patency | 2020 |
One-year results of drug-coated balloons for long and occlusive Femoropopliteal artery disease: a single-arm trial.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Beijing; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Patency | 2020 |
Paclitaxel-Coated Balloon versus Plain Balloon Angioplasty for Dysfunctional Autogenous Radiocephalic Arteriovenous Fistulas: A Prospective Randomized Controlled Trial.
Topics: Aged; Angioplasty, Balloon; Arteriovenous Fistula; Arteriovenous Shunt, Surgical; Constriction, Pathologic; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Renal Dialysis; Single-Blind Method; Treatment Outcome; Vascular Patency | 2020 |
Drug-Coated Balloons for Dysfunctional Dialysis Arteriovenous Fistulas.
Topics: Aged; Angioplasty, Balloon; Arteriovenous Shunt, Surgical; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Renal Dialysis; Single-Blind Method; Upper Extremity; Vascular Access Devices; Vascular Patency | 2020 |
Efficacy and Safety of Paclitaxel-Coated Balloon Angioplasty for Dysfunctional Arteriovenous Fistulas: A Multicenter Randomized Controlled Trial.
Topics: Adult; Aged; Angioplasty, Balloon; Arteriovenous Shunt, Surgical; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Humans; Male; Middle Aged; Paclitaxel; Postoperative Complications; Prospective Studies; Renal Dialysis; Treatment Outcome; Vascular Patency | 2021 |
Intervention with selution SLR™ Agent Balloon for Endovascular Latent Limus therapy for failing AV Fistulas (ISABELLA) Trial: Protocol for a pilot clinical study and pre-clinical results.
Topics: Angioplasty, Balloon; Arteriovenous Fistula; Coated Materials, Biocompatible; Constriction, Pathologic; Humans; Paclitaxel; Pilot Projects; Prospective Studies; Renal Dialysis; Sirolimus; Treatment Outcome; Vascular Patency | 2023 |
One-Year Outcomes of the Paclitaxel-Eluting, Self-Expanding Stentys Stent System in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia.
Topics: Aged; Aged, 80 and over; Alloys; Angiography; Belgium; Cardiovascular Agents; Constriction, Pathologic; Critical Illness; Drug-Eluting Stents; Endovascular Procedures; Female; Humans; Ischemia; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Risk Factors; Self Expandable Metallic Stents; Time Factors; Treatment Outcome; Vascular Patency | 2017 |
ISAR-PEBIS (Paclitaxel-Eluting Balloon Versus Conventional Balloon Angioplasty for In-Stent Restenosis of Superficial Femoral Artery): A Randomized Trial.
Topics: Aged; Aged, 80 and over; Angiography; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Disease-Free Survival; Endovascular Procedures; Equipment Design; Female; Femoral Artery; Germany; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Recurrence; Stents; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2017 |
12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Europe; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2018 |
Drug Coated Balloon Angioplasty in Failing AV Fistulas: A Randomized Controlled Trial.
Topics: Angioplasty, Balloon; Arteriovenous Shunt, Surgical; Coated Materials, Biocompatible; Constriction, Pathologic; Drug Carriers; Equipment Design; Female; Humans; Male; Middle Aged; Paclitaxel; Postoperative Complications; Time Factors; Treatment Outcome | 2018 |
Sustainable Antirestenosis Effect With a Low-Dose Drug-Coated Balloon: The ILLUMENATE European Randomized Clinical Trial 2-Year Results.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Europe; Female; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Recurrence; Risk Factors; Single-Blind Method; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2018 |
Comparison of 2 Different Drug-Coated Balloons in In-Stent Restenosis: The RESTORE ISR China Randomized Trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiac Catheters; Cardiovascular Agents; China; Coated Materials, Biocompatible; Constriction, Pathologic; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Equipment Design; Female; Humans; Male; Middle Aged; Paclitaxel; Percutaneous Coronary Intervention; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2018 |
Clinical Randomized Trial Evaluating Novel, Microcrystalline, and Biocompatible Polymer Paclitaxel-Coated Balloon for the Treatment of Femoropopliteal Occlusive Disease: The BIOPAC Trial.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Poland; Popliteal Artery; Prospective Studies; Single-Blind Method; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2018 |
Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The Chronic Total Occlusion Cohort in the IN.PACT Global Study.
Topics: Aged; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Chronic Disease; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Female; Femoral Artery; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Progression-Free Survival; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Time Factors; Vascular Access Devices; Vascular Patency | 2019 |
Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.
Topics: Aged; Alloys; Angioplasty, Balloon; Ankle Brachial Index; Canada; Cardiovascular Agents; Constriction, Pathologic; Disease-Free Survival; Drug-Eluting Stents; Europe; Exercise Test; Female; Femoral Artery; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Prosthesis Failure; Recurrence; Registries; Republic of Korea; Risk Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vascular Patency | 2013 |
Randomized trial of Legflow(®) paclitaxel eluting balloon and stenting versus standard percutaneous transluminal angioplasty and stenting for the treatment of intermediate and long lesions of the superficial femoral artery (RAPID trial): study protocol fo
Topics: Alloys; Amputation, Surgical; Angiography, Digital Subtraction; Angioplasty, Balloon; Ankle Brachial Index; Arterial Occlusive Diseases; Cardiovascular Agents; Clinical Protocols; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Equipment Failure; Femoral Artery; Hemodynamics; Humans; Hyperplasia; Limb Salvage; Neointima; Netherlands; Paclitaxel; Predictive Value of Tests; Prosthesis Design; Prosthesis Failure; Recurrence; Research Design; Resins, Plant; Single-Blind Method; Stents; Surveys and Questionnaires; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Access Devices | 2013 |
Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery).
Topics: Aged; Aged, 80 and over; Alloys; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Disease-Free Survival; Equipment Design; Female; Femoral Artery; Humans; Italy; Kaplan-Meier Estimate; Limb Salvage; Male; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Radiography; Recurrence; Risk Factors; Stents; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2013 |
High-grade, non-flow-limiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: an additional analysis from the THUNDER study.
Topics: Aged; Angioplasty, Balloon; Aortic Dissection; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Double-Blind Method; Equipment Design; Female; Femoral Artery; Germany; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Radiography; Recurrence; Regional Blood Flow; Retreatment; Risk Factors; Stents; Time Factors; Treatment Outcome; Vascular Access Devices | 2013 |
The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Drug Carriers; Equipment Design; Europe; Female; Femoral Artery; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Polysorbates; Popliteal Artery; Radiography; Secondary Prevention; Sorbitol; Time Factors; Treatment Outcome; Vascular Access Devices | 2014 |
Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angiography, Digital Subtraction; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Drug-Eluting Stents; Female; Greece; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Recurrence; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency; Vascular Remodeling | 2014 |
Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Constriction, Pathologic; Disease-Free Survival; Drug-Eluting Stents; Female; Femoral Artery; Germany; Humans; Japan; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Prosthesis Failure; Reproducibility of Results; Research Design; Time Factors; Treatment Outcome; United States; Vascular Patency | 2014 |
Bare metal stent versus paclitaxel eluting stent for intermediate length femoropopliteal arterial lesions (BATTLE trial): study protocol for a randomized controlled trial.
Topics: Cardiovascular Agents; Clinical Protocols; Constriction, Pathologic; Drug-Eluting Stents; Endovascular Procedures; Femoral Artery; France; Humans; Metals; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Recurrence; Research Design; Stents; Switzerland; Time Factors; Treatment Outcome | 2014 |
Drug-eluting versus plain balloon angioplasty for the treatment of failing dialysis access: final results and cost-effectiveness analysis from a prospective randomized controlled trial (NCT01174472).
Topics: Aged; Angioplasty, Balloon; Arteriovenous Shunt, Surgical; Constriction, Pathologic; Cost-Benefit Analysis; Drug Delivery Systems; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Paclitaxel; Prospective Studies; Renal Dialysis; Treatment Outcome; Tubulin Modulators | 2015 |
Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial.
Topics: Aged; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Female; Femoral Artery; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Predictive Value of Tests; Radiography; Recurrence; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Access Devices | 2015 |
German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Germany; Humans; Intermittent Claudication; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Single-Blind Method; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2016 |
Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease.
Topics: Aged; Alloys; Ankle Brachial Index; Australia; Blood Flow Velocity; Cardiovascular Agents; Chronic Disease; Constriction, Pathologic; Drug-Eluting Stents; Endovascular Procedures; Europe; Female; Femoral Artery; Humans; Ischemia; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; New Zealand; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Regional Blood Flow; Self Expandable Metallic Stents; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Patency | 2016 |
Local Ultrasound to Enhance Paclitaxel Delivery After Femoral-Popliteal Treatment in Critical Limb Ischemia: The PACUS Trial.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Catheterization, Peripheral; Coated Materials, Biocompatible; Constriction, Pathologic; Critical Illness; Equipment Design; Female; Femoral Artery; Humans; Ischemia; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Single-Blind Method; Time Factors; Treatment Outcome; Ultrasonic Therapy; Ultrasonography, Interventional; Vascular Access Devices; Vascular Patency | 2016 |
The effectiveness of the paclitaxel-coated Luminor® balloon catheter versus an uncoated balloon catheter in superficial femoral and popliteal arteries in preventing vessel restenosis or reocclusion: study protocol for a randomized controlled trial.
Topics: Angiography, Digital Subtraction; Angioplasty, Balloon; Ankle Brachial Index; Cardiovascular Agents; Clinical Protocols; Coated Materials, Biocompatible; Computed Tomography Angiography; Constriction, Pathologic; Exercise Tolerance; Female; Femoral Artery; Germany; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Quality of Life; Recovery of Function; Recurrence; Research Design; Risk Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Access Devices; Vascular Patency; Walking | 2016 |
Sealing Intermediate Nonobstructive Coronary Saphenous Vein Graft Lesions With Drug-Eluting Stents as a New Approach to Reducing Cardiac Events: A Randomized Controlled Trial.
Topics: Aged; Canada; Cardiovascular Agents; Constriction, Pathologic; Coronary Angiography; Coronary Artery Bypass; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Percutaneous Coronary Intervention; Prosthesis Design; Risk Factors; Saphenous Vein; Severity of Illness Index; Time Factors; Treatment Outcome; Vascular Patency | 2016 |
Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Cilostazol; Constriction, Pathologic; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Japan; Logistic Models; Male; Middle Aged; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Popliteal Artery; Propensity Score; Prospective Studies; Prosthesis Design; Recurrence; Registries; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Patency | 2017 |
Update on PADI trial: percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia.
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Cardiovascular Agents; Constriction, Pathologic; Critical Illness; Drug-Eluting Stents; Humans; Ischemia; Lower Extremity; Metals; Netherlands; Paclitaxel; Popliteal Artery; Prospective Studies; Prosthesis Design; Research Design; Secondary Prevention; Stents; Treatment Outcome | 2009 |
Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic End
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Constriction, Pathologic; Coronary Angiography; Coronary Artery Disease; Cost-Benefit Analysis; Drug-Eluting Stents; Female; Health Care Costs; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Models, Economic; Myocardial Infarction; Paclitaxel; Prospective Studies; Prosthesis Design; Quality of Life; Quality-Adjusted Life Years; Risk Assessment; Single-Blind Method; Sirolimus; Time Factors; Treatment Outcome; United States | 2009 |
Long-term outcome of adjunctive celecoxib treatment after paclitaxel-eluting stent implantation for the complex coronary lesions: two-year clinical follow-up of COREA-TAXUS trial.
Topics: Aged; Celecoxib; Chemotherapy, Adjuvant; Constriction, Pathologic; Coronary Vessels; Cyclooxygenase 2 Inhibitors; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Prosthesis Implantation; Pyrazoles; Sulfonamides; Treatment Outcome | 2010 |
Paclitaxel-coated balloon angioplasty vs. plain balloon dilation for the treatment of failing dialysis access: 6-month interim results from a prospective randomized controlled trial.
Topics: Aged; Angioplasty, Balloon; Arteriovenous Shunt, Surgical; Blood Vessel Prosthesis Implantation; Cardiovascular Agents; Catheters; Constriction, Pathologic; Drug Delivery Systems; Equipment Design; Female; Graft Occlusion, Vascular; Greece; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Prospective Studies; Radiography; Renal Dialysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2012 |
Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Arterial Occlusive Diseases; Cardiovascular Agents; Constriction, Pathologic; Drug Carriers; Equipment Design; Female; Femoral Artery; Humans; Limb Salvage; Lower Extremity; Male; Middle Aged; Paclitaxel; Popliteal Artery; Prospective Studies; Radiography; Recurrence; Rome; Severity of Illness Index; Stents; Thrombosis; Time Factors; Treatment Outcome; Vascular Access Devices | 2012 |
Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Arterial Occlusive Diseases; Cardiovascular Agents; Chi-Square Distribution; Coated Materials, Biocompatible; Constriction, Pathologic; Drug Carriers; Equipment Design; Female; Femoral Artery; Germany; Humans; Kaplan-Meier Estimate; Likelihood Functions; Linear Models; Male; Middle Aged; Paclitaxel; Popliteal Artery; Proportional Hazards Models; Radiography; Secondary Prevention; Time Factors; Treatment Outcome; Vascular Access Devices | 2012 |
[Comparison of Rapamycin and Paclitaxel eluting stent in patients with multi-vessel coronary disease].
Topics: Angioplasty, Balloon, Coronary; Constriction, Pathologic; Coronary Disease; Drug-Eluting Stents; Follow-Up Studies; Humans; Paclitaxel; Sirolimus; Treatment Outcome | 2006 |
117 other study(ies) available for paclitaxel and Constriction, Pathological
| Article | Year |
|---|---|
Combination of paclitaxel and nitric oxide as a novel treatment for the reduction of restenosis.
Topics: Adamantane; Animals; Antineoplastic Agents; Constriction, Pathologic; Iliac Artery; In Vitro Techniques; Muscle, Smooth, Vascular; Nitric Oxide; Nitric Oxide Donors; Nitroso Compounds; Paclitaxel; Platelet Aggregation Inhibitors; Rabbits; Recurrence; Stents; Vascular Diseases | 2004 |
Drug-Coated Balloon Angioplasty Versus Standard Uncoated Balloon Angioplasty for Long Femoropopliteal Lesions: Post Hoc Analysis of the 24-Month Results of the AcoArt I Study.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Constriction, Pathologic; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Time Factors; Treatment Outcome; Vascular Patency | 2022 |
Recurrent Stenoses in Arteriovenous Fistula (AVF) for Dialysis Access: cuttIng ballooN angioplaSTy combined wITh paclitaxel drUg-coaTed balloon angioplasty, an observatIONal study (INSTITUTION Study).
Topics: Angioplasty, Balloon; Arteriovenous Fistula; Arteriovenous Shunt, Surgical; Coated Materials, Biocompatible; Cohort Studies; Constriction, Pathologic; Humans; Paclitaxel; Prospective Studies; Renal Dialysis; Treatment Outcome; Vascular Patency | 2022 |
Long-term outcomes of paclitaxel-coated balloons for non-malignant ureteral strictures.
Topics: Constriction, Pathologic; Female; Humans; Male; Paclitaxel; Pilot Projects; Prospective Studies; Treatment Outcome; Ureteral Obstruction | 2022 |
Concomitant Drug-Coated Balloon Angioplasty With Bail-Out Use of Eluvia Drug-Eluting Stent: Is There Any Downside to a Double Dose of Paclitaxel?
Topics: Angioplasty, Balloon; Constriction, Pathologic; Drug-Eluting Stents; Humans; Paclitaxel; Pharmaceutical Preparations; Retrospective Studies | 2022 |
Efficacy and Safety Differences between Domestic Paclitaxel Drug-Coated Balloons and Metal Bare Stents in the Treatment of ASO of Femoral-Popliteal Arteries Type IIA-C.
Topics: Arteriosclerosis Obliterans; Coated Materials, Biocompatible; Constriction, Pathologic; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Stents; Treatment Outcome | 2022 |
Analysis of Inhibitory Effect of the Double-layer Nano-infusion on Vascular Restenosis in Animal Models of Coronary Atherosclerosis.
Topics: Animals; Apolipoproteins E; Constriction, Pathologic; Coronary Artery Disease; Mice; Models, Animal; Nanoparticle Drug Delivery System; Nanoparticles; Paclitaxel; Vascular Endothelial Growth Factor A | 2022 |
Combined Analysis of Two Parallel Randomized Trials of Sirolimus-Coated and Paclitaxel-Coated Balloons in Coronary In-Stent Restenosis Lesions.
Topics: Angioplasty, Balloon, Coronary; Constriction, Pathologic; Coronary Restenosis; Drug-Eluting Stents; Humans; Paclitaxel; Polychlorinated Biphenyls; Randomized Controlled Trials as Topic; Sirolimus; Stents; Treatment Outcome | 2022 |
Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention.
Topics: Aged; Angioplasty, Balloon; Carcinoma, Renal Cell; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Humans; Kidney Neoplasms; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2022 |
Two-year clinical outcomes and predictors of restenosis following the use of polymer-coated paclitaxel-eluting stents or drug-coated balloons in patients with femoropopliteal artery disease.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Constriction, Pathologic; Drug-Eluting Stents; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Stents; Treatment Outcome; Vascular Patency | 2023 |
Euonymine inhibits in-stent restenosis through enhancing contractile phenotype of vascular smooth muscle cells via modulating the PTEN/AKT/mTOR signaling pathway.
Topics: Animals; bcl-2-Associated X Protein; Caspase 3; Constriction, Pathologic; Coronary Angiography; Coronary Restenosis; Muscle, Smooth, Vascular; Paclitaxel; Percutaneous Coronary Intervention; Phenotype; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rabbits; Risk Factors; Signal Transduction; Sirolimus; Swine; TOR Serine-Threonine Kinases; Treatment Outcome | 2022 |
Vascular healing responses to paclitaxel coated balloons or everolimus eluting stents for the treatment of in-stent restenosis. Insights from optical coherence tomography.
Topics: Angioplasty, Balloon, Coronary; Constriction, Pathologic; Coronary Angiography; Coronary Restenosis; Drug-Eluting Stents; Everolimus; Humans; Metals; Paclitaxel; Prospective Studies; Stents; Tomography, Optical Coherence; Treatment Outcome | 2022 |
Drug-Coated Balloons: Drugs Beyond Paclitaxel?
Topics: Angioplasty, Balloon, Coronary; Animals; Coated Materials, Biocompatible; Constriction, Pathologic; Paclitaxel; Stents; Swine; Treatment Outcome | 2022 |
One single drug-coated balloon for all shapes/diameters? Neointimal proliferation inhibition in porcine peripheral arteries.
Topics: Angioplasty, Balloon; Animals; Cell Proliferation; Coated Materials, Biocompatible; Constriction, Pathologic; Coronary Vessels; Neointima; Paclitaxel; Stents; Swine | 2023 |
Safety and Efficacy of the Passeo-18 Lux Drug-Coated Balloon Catheter in Atherosclerotic Femoropopliteal Lesions: The Multicenter BIOLUX P-IV China Study.
Topics: Aged; Angioplasty, Balloon; Atherosclerosis; Catheters; China; Coated Materials, Biocompatible; Constriction, Pathologic; Femoral Artery; Humans; Limb Salvage; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Treatment Outcome; Vascular Patency | 2023 |
Superficial Femoral Artery in-Stent Restenosis Treated with Paclitaxel-Coated Balloon Angioplasty - Results of Three-Year Follow-Up.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Constriction, Pathologic; Coronary Restenosis; Femoral Artery; Follow-Up Studies; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome; Vascular Patency | 2023 |
Cost-Effectiveness of Drug-Coated Balloon Angioplasty versus Plain Old Balloon Angioplasty for Arteriovenous Fistula Stenosis.
Topics: Aged; Angioplasty, Balloon; Arteriovenous Fistula; Coated Materials, Biocompatible; Constriction, Pathologic; Cost-Benefit Analysis; Humans; Medicare; Paclitaxel; Peripheral Arterial Disease; Treatment Outcome; United States | 2023 |
Crystalline sirolimus-coated balloon (cSCB) angioplasty in an all-comers, patient population with stable and unstable coronary artery disease including chronic total occlusions: rationale, methodology and design of the SCORE trial.
Topics: Angioplasty; Cardiovascular Agents; Clinical Trials as Topic; Constriction, Pathologic; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Humans; Paclitaxel; Sirolimus; Treatment Outcome | 2023 |
Clinical and Angiographic Outcomes of Elective Paclitaxel-Coated Balloon Angioplasty in Comparison with Drug-Eluting Stents for De Novo Coronary Lesions in Large Vessels.
Topics: Angioplasty, Balloon, Coronary; Constriction, Pathologic; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Humans; Paclitaxel; Retrospective Studies; Stents; Treatment Outcome | 2023 |
Propensity score-matched analysis of six-month outcomes of paclitaxel-coated balloons combined with UltraScore balloons versus conventional scoring balloons for femoropopliteal lesions.
Topics: Angioplasty, Balloon; Constriction, Pathologic; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Propensity Score; Retrospective Studies; Treatment Outcome; Vascular Patency | 2023 |
Poor Below Knee Runoff Impacts Femoropopliteal Stent Failure and Fluoropolymer Antithrombotic Effect in Healthy Swine Model.
Topics: Animals; Constriction, Pathologic; Drug-Eluting Stents; Femoral Artery; Fibrinolytic Agents; Fluorocarbon Polymers; Neointima; Paclitaxel; Polymers; Stents; Swine; Thrombosis; Treatment Outcome | 2023 |
Paclitaxel-coated balloons are safe for the treatment of arterial stenoses.
Topics: Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome; Vascular Diseases | 2023 |
Turbo-Power™ Laser Atherectomy Combined with Drug-coated Balloon Angioplasty is Associated with Improved One-Year Outcomes for the Treatment of Tosaka II and III Femoropopliteal In-stent Restenosis.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Atherectomy; California; Cardiovascular Agents; Coated Materials, Biocompatible; Colorado; Constriction, Pathologic; Female; Femoral Artery; Humans; Laser Therapy; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Recurrence; Retrospective Studies; Stents; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2020 |
Adventitial injection delivery of nano-encapsulated sirolimus (Nanolimus) to injury-induced porcine femoral vessels to reduce luminal restenosis.
Topics: Animals; Constriction, Pathologic; Female; Femoral Artery; Lower Extremity; Neointima; Paclitaxel; Sirolimus; Swine | 2020 |
Editor's Choice - Long Term Survival after Femoropopliteal Artery Revascularisation with Paclitaxel Coated Devices: A Propensity Score Matched Cohort Analysis.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Constriction, Pathologic; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Retrospective Studies; Vascular Access Devices | 2020 |
Drug-Coated Balloon Dilation Compared With Conventional Stenting Angioplasty for Intracranial Atherosclerotic Disease.
Topics: Aged; Angioplasty, Balloon; Coated Materials, Biocompatible; Constriction, Pathologic; Endovascular Procedures; Female; Humans; Intracranial Arteriosclerosis; Male; Middle Aged; Paclitaxel; Recurrence; Retrospective Studies; Stents; Treatment Outcome | 2020 |
Kounis Syndrome after Angioplasty of the Superficial Femoral Artery with Paclitaxel-Coated Balloon.
Topics: Aged; Anaphylaxis; Angioplasty, Balloon; Cardiovascular Agents; Constriction, Pathologic; Drug Hypersensitivity; Female; Femoral Artery; Humans; Kounis Syndrome; Paclitaxel; Peripheral Arterial Disease; Treatment Outcome; Vascular Access Devices | 2020 |
Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recovery of Function; Registries; Severity of Illness Index; Time Factors; Treatment Outcome; Vascular Patency | 2020 |
Outcomes of Dissection Angles as Predictor of Restenosis after Drug-Coated Balloon Treatment.
Topics: Aged; Aged, 80 and over; Constriction, Pathologic; Endovascular Procedures; Female; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Prognosis; Retrospective Studies; Treatment Outcome; Tubulin Modulators; Vascular Access Devices | 2021 |
Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis.
Topics: Aged; Antineoplastic Agents, Phytogenic; Centers for Medicare and Medicaid Services, U.S.; Constriction, Pathologic; Drug-Eluting Stents; Female; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Registries; Time Factors; United States | 2021 |
Drug-coated balloons - the golden tool for treatment of stenotic lesions in dysfunctional haemodialysis fistulas?
Topics: Angioplasty, Balloon; Arteriovenous Shunt, Surgical; Coated Materials, Biocompatible; Constriction, Pathologic; Fistula; Humans; Paclitaxel; Pharmaceutical Preparations; Renal Dialysis; Treatment Outcome | 2021 |
Paclitaxel-Coated Balloons for the Treatment of Symptomatic Central Venous Stenosis in Vascular Access: Results From a European, Multicenter, Single-Arm Retrospective Analysis.
Topics: Angioplasty, Balloon; Arteriovenous Shunt, Surgical; Child, Preschool; Constriction, Pathologic; Europe; Humans; Infant; Middle Aged; Paclitaxel; Renal Dialysis; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Patency; Vena Cava, Superior | 2021 |
Comparison of functional patency rates between paclitaxel-eluting versus plain balloon angioplasty in hemodialysis patients with central venous stenosis: An intra-individual comparison study.
Topics: Adult; Aged; Angioplasty, Balloon; Constriction, Pathologic; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Renal Dialysis; Treatment Outcome; Tubulin Modulators; Vascular Patency | 2022 |
Efficacy and one-year outcomes of Luminor® paclitaxel-coated drug-eluting balloon in the treatment of popliteal artery atherosclerosis lesions.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Critical Illness; Equipment Design; Female; Humans; Intermittent Claudication; Ischemia; Limb Salvage; Male; Paclitaxel; Peripheral Arterial Disease; Plaque, Atherosclerotic; Popliteal Artery; Prospective Studies; Recurrence; Severity of Illness Index; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2021 |
Paclitaxel-coated balloon angioplasty for recurrent arteriovenous fistula stenosis.
Topics: Angioplasty, Balloon; Arteriovenous Fistula; Arteriovenous Shunt, Surgical; Constriction, Pathologic; Humans; Paclitaxel | 2021 |
First-in-man experience of self-expanding nitinol stents combined with drug-coated balloon in the treatment of femoropopliteal occlusive disease.
Topics: Aged; Alloys; Angioplasty, Balloon; Australia; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Endovascular Procedures; Female; Femoral Artery; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Self Expandable Metallic Stents; Severity of Illness Index; Time Factors; Treatment Outcome; Vascular Patency | 2018 |
Impact of Fluoropolymer-Based Paclitaxel Delivery on Neointimal Proliferation and Vascular Healing: A Comparative Peripheral Drug-Eluting Stent Study in the Familial Hypercholesterolemic Swine Model of Femoral Restenosis.
Topics: Angiography; Animals; Cardiovascular Agents; Cell Proliferation; Constriction, Pathologic; Disease Models, Animal; Drug-Eluting Stents; Endovascular Procedures; Femoral Artery; Hyperlipoproteinemia Type II; Methacrylates; Neointima; Paclitaxel; Peripheral Arterial Disease; Polymers; Polyvinyls; Prosthesis Design; Recurrence; Sus scrofa; Time Factors; Tomography, Optical Coherence; Vascular Patency; Wound Healing | 2017 |
A universal drug delivery catheter for the treatment of infrapopliteal arterial disease: Results from the multi-center first-in-human study.
Topics: Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Catheterization, Peripheral; Constriction, Pathologic; Feasibility Studies; Female; Humans; Limb Salvage; Lower Extremity; Male; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Recurrence; Registries; Risk Factors; Thrombosis; Time Factors; Treatment Outcome; United States; Vascular Access Devices; Vascular Patency | 2018 |
A Pilot Study of Femoropopliteal Artery Revascularisation with a Low Dose Paclitaxel Coated Balloon: Is Predilatation Necessary?
Topics: Aged; Angioplasty, Balloon; Ankle Brachial Index; Cardiovascular Agents; Chi-Square Distribution; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Germany; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Pilot Projects; Popliteal Artery; Propensity Score; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2017 |
Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort.
Topics: Aged; Amputation, Surgical; Angiography; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Endovascular Procedures; Female; Femoral Artery; Humans; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Stents; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Access Devices; Vascular Patency | 2017 |
Freeway paclitaxel-releasing balloons to treat recurrent stenosis of arteriovenous fistula in hemodialysis patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Arteriovenous Fistula; Constriction, Pathologic; Endovascular Procedures; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Recurrence; Renal Dialysis; Time Factors; Young Adult | 2018 |
Evaluation of the Distribution of Paclitaxel After Application of a Paclitaxel-Coated Balloon in the Rabbit Urethra.
Topics: Animals; Catheterization; Constriction, Pathologic; Disease Models, Animal; Drug Delivery Systems; Male; Paclitaxel; Rabbits; Tubulin Modulators; Urethra; Urethral Stricture; Urothelium | 2018 |
Endovascular Treatment of Haemodialysis Arteriovenous Fistula with Drug-Coated Balloon Angioplasty: A Single-Centre Study.
Topics: Aged; Angioplasty, Balloon; Arteriovenous Shunt, Surgical; Constriction, Pathologic; Endovascular Procedures; Female; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; Paclitaxel; Renal Dialysis; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2018 |
Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain: 2-Year Results From the IN.PACT Global Study.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2018 |
1-Year All-Comers Analysis of the Eluvia Drug-Eluting Stent for Long Femoropopliteal Lesions After Suboptimal Angioplasty.
Topics: Aged; Angioplasty; Cardiovascular Agents; Chronic Disease; Constriction, Pathologic; Drug-Eluting Stents; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Calcification; Vascular Patency | 2018 |
Safety and effectiveness of combined scoring balloon and paclitaxel-coated balloon angioplasty for stenosis in the hemodialysis access circuit.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Arteriovenous Shunt, Surgical; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Humans; Male; Middle Aged; Paclitaxel; Renal Dialysis; Vascular Patency | 2019 |
Paclitaxel drug-coated balloon angioplasty for the treatment of failing arteriovenous fistulas: a single-center experience.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Antineoplastic Agents, Phytogenic; Arteriovenous Shunt, Surgical; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Paclitaxel; Renal Dialysis; Retrospective Studies | 2020 |
One-Year Clinical Outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Critical Illness; Equipment Design; Europe; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Registries; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2019 |
An electrospun fiber-covered stent with programmable dual drug release for endothelialization acceleration and lumen stenosis prevention.
Topics: Animals; Antineoplastic Agents; Blood Vessel Prosthesis; Cell Survival; Coated Materials, Biocompatible; Constriction, Pathologic; Dogs; Drug Delivery Systems; Drug Liberation; Drug-Eluting Stents; Female; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Intracranial Aneurysm; Male; Nanofibers; Nanoparticles; Paclitaxel; Polyesters; Polymers; Porosity; Prostheses and Implants; Silicon Dioxide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2019 |
Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cardiovascular Agents; Cilostazol; Constriction, Pathologic; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Japan; Limb Salvage; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Progression-Free Survival; Prosthesis Design; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Vascular Calcification; Vascular Patency | 2019 |
2-year results of paclitaxel-eluting balloons for femoropopliteal artery disease: evidence from a multicenter registry.
Topics: Aged; Angioplasty, Balloon; Ankle Brachial Index; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Exercise Test; Female; Femoral Artery; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Quality of Life; Recurrence; Registries; Stents; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2013 |
How should I treat a restenosis after superficial femoral artery stenting?
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Predictive Value of Tests; Recurrence; Stents; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography, Doppler; Vascular Access Devices | 2013 |
Evaluation of biodegradable paclitaxel-eluting nanofibre-covered metal stents for the treatment of benign cardia stricture in an experimental model.
Topics: Absorbable Implants; Animals; Antimitotic Agents; Benzalkonium Compounds; Cardia; Cell Proliferation; Constriction, Pathologic; Dogs; Drug-Eluting Stents; Female; Male; Muscle, Smooth; Nanofibers; Paclitaxel; Random Allocation; Stomach Diseases | 2013 |
Stent healing response following delivery of paclitaxel via durable polymeric matrix versus iopromide-based balloon coating in the familial hypercholesterolaemic swine model of coronary injury.
Topics: Angioplasty, Balloon, Coronary; Animals; Cardiovascular Agents; Constriction, Pathologic; Coronary Artery Disease; Coronary Vessels; Disease Models, Animal; Drug-Eluting Stents; Iohexol; Neointima; Paclitaxel; Polymers; Swine | 2013 |
Tissue uptake, distribution, and healing response after delivery of paclitaxel via second-generation iopromide-based balloon coating: a comparison with the first-generation technology in the iliofemoral porcine model.
Topics: Angioplasty, Balloon; Animals; Arterial Occlusive Diseases; Cardiovascular Agents; Cell Proliferation; Coated Materials, Biocompatible; Constriction, Pathologic; Contrast Media; Disease Models, Animal; Equipment Design; Femoral Artery; Fibrosis; Hyperlipoproteinemia Type II; Iliac Artery; Iohexol; Neointima; Paclitaxel; Radiography; Sus scrofa; Tissue Distribution; Vascular Access Devices; Wound Healing | 2013 |
Nitinol stents with polymer-free paclitaxel coating for stenosis of failing infrainguinal bypass grafts.
Topics: Aged; Aged, 80 and over; Alloys; Angioplasty, Balloon; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cardiovascular Agents; Constriction, Pathologic; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Humans; Italy; Lower Extremity; Male; Middle Aged; Paclitaxel; Prosthesis Design; Prosthesis Failure; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Patency | 2013 |
Cost-effectiveness analysis of paclitaxel-coated balloons for endovascular therapy of femoropopliteal arterial obstructions.
Topics: Angioplasty, Balloon; Budgets; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Equipment Design; Femoral Artery; Health Care Costs; Health Expenditures; Hospital Costs; Humans; Insurance, Health, Reimbursement; Length of Stay; Models, Economic; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Vascular Access Devices | 2013 |
[A case of rectal stenosis due to peritoneal dissemination from gastric cancer that was treated with chemoradiation therapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Chemoradiotherapy; Constriction, Pathologic; Drug Combinations; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Rectal Diseases; Stomach Neoplasms; Tegafur | 2013 |
Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Diabetic Angiopathies; Equipment Design; Female; Femoral Artery; Humans; Italy; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Radiography; Retreatment; Risk Factors; Secondary Prevention; Time Factors; Treatment Outcome; Ultrasonography; Vascular Access Devices | 2014 |
Paclitaxel coating on the terminal portion of hemodialysis grafts effectively suppresses neointimal hyperplasia in a porcine model.
Topics: Animals; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cardiovascular Agents; Carotid Artery, Common; Coated Materials, Biocompatible; Constriction, Pathologic; Disease Models, Animal; Female; Graft Occlusion, Vascular; Hyperplasia; Jugular Veins; Neointima; Paclitaxel; Polytetrafluoroethylene; Prosthesis Design; Renal Dialysis; Swine; Time Factors | 2015 |
Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Femoral Artery; Follow-Up Studies; Humans; Italy; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Recurrence; Registries; Retreatment; Stents; Time Factors; Treatment Outcome; Vascular Access Devices | 2014 |
Paclitaxel-coated balloons for failing peripheral bypass grafts: the BYPACS study.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angiography, Digital Subtraction; Angioplasty, Balloon; Blood Flow Velocity; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cardiovascular Agents; Constriction, Pathologic; Drug Carriers; Equipment Design; Female; Graft Occlusion, Vascular; Humans; Kaplan-Meier Estimate; Limb Salvage; London; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Peripheral Arterial Disease; Proportional Hazards Models; Prospective Studies; Prosthesis Failure; Regional Blood Flow; Reoperation; Risk Factors; Time Factors; Treatment Failure; Ultrasonography, Doppler, Duplex; Vascular Access Devices; Veins | 2014 |
Effectiveness of Zilver PTX eluting stent in TASC C/D lesions and restenosis.
Topics: Aged; Aged, 80 and over; Alloys; Cardiovascular Agents; Constriction, Pathologic; Disease-Free Survival; Drug-Eluting Stents; Endovascular Procedures; Female; Humans; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prosthesis Design; Recurrence; Time Factors; Treatment Outcome; Ultrasonography, Doppler; Vascular Patency | 2014 |
Paclitaxel-coated balloons in refractory nonanastomostic airway stenosis following lung transplantation.
Topics: Adult; Antineoplastic Agents, Phytogenic; Bronchi; Constriction, Pathologic; Female; Humans; Lung Transplantation; Male; Middle Aged; Paclitaxel | 2014 |
Paclitaxel-eluting nanofiber-covered self-expanding nonvascular stent for palliative chemotherapy of gastrointestinal cancer and its related stenosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Coated Materials, Biocompatible; Colonic Neoplasms; Constriction, Pathologic; Drug-Eluting Stents; Humans; Mice; Mice, Inbred BALB C; Nanofibers; Paclitaxel; Palliative Care | 2014 |
Drug-eluting balloons for femoropopliteal lesions show better performance in de novo stenosis or occlusion than in restenosis.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Critical Illness; Equipment Design; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Stents; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2015 |
Biological effect of orbital atherectomy and adjunctive paclitaxel-coated balloon therapy on vascular healing and drug retention: early experimental insights into the familial hypercholesterolaemic swine model of femoral artery stenosis.
Topics: Angioplasty, Balloon; Animals; Antineoplastic Agents, Phytogenic; Atherectomy; Combined Modality Therapy; Constriction, Pathologic; Disease Models, Animal; Femoral Artery; Hyperlipoproteinemia Type II; Paclitaxel; Peripheral Arterial Disease; Swine; Tomography, Optical Coherence; Ultrasonography, Interventional; Wound Healing | 2014 |
Outcomes of Zilver PTX stent implantation for the treatment of complex femoropopliteal artery disease.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Constriction, Pathologic; Disease-Free Survival; Drug-Eluting Stents; Femoral Artery; Humans; Japan; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Recurrence; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Patency | 2016 |
Paclitaxel-eluting balloon dilation of biliary anastomotic stricture after liver transplantation.
Topics: Adult; Catheters; Cholangiopancreatography, Endoscopic Retrograde; Cholestasis; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Feasibility Studies; Female; Germany; Hospitals, University; Humans; Liver Transplantation; Male; Middle Aged; Paclitaxel; Pilot Projects; Prospective Studies; Recurrence; Time Factors; Treatment Outcome | 2015 |
Intravascular ultrasound measurements after drug-eluting stent placement in femoropopliteal lesions: determining predictors of restenosis.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Area Under Curve; Blood Flow Velocity; Cardiovascular Agents; Constriction, Pathologic; Critical Illness; Drug-Eluting Stents; Female; Femoral Artery; Humans; Ischemia; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Predictive Value of Tests; Prosthesis Design; Radiography; Recurrence; Regional Blood Flow; Retrospective Studies; Risk Factors; ROC Curve; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Ultrasonography, Interventional | 2015 |
Temporary placement of a paclitaxel or rapamycin-eluting stent is effective to reduce stenting induced inflammatory reaction and scaring in benign cardia stricture models.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Cardia; Cicatrix; Constriction, Pathologic; Disease Models, Animal; Dogs; Drug-Eluting Stents; Esophageal Sphincter, Lower; Esophageal Stenosis; Female; Humans; Inflammation; Male; Manometry; Paclitaxel; Random Allocation; Sirolimus; Time Factors | 2014 |
[Efficacy of balloon catheters with antiproliferative cover in patients with impairment of arteries of femoral-popliteal segment].
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Coated Materials, Biocompatible; Constriction, Pathologic; Cytostatic Agents; Femoral Artery; Humans; Paclitaxel; Popliteal Artery; Recurrence; Treatment Outcome; Vascular Access Devices | 2015 |
Drug-Eluting vs Standard Balloon Angioplasty for Iliac Stent Restenosis: Midterm Results.
Topics: Aged; Angioplasty, Balloon; Ankle Brachial Index; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Humans; Iliac Artery; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Radiography; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Stents; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Color; Vascular Access Devices; Vascular Patency | 2015 |
Optimization of Drug Delivery by Drug-Eluting Stents.
Topics: Algorithms; Atherosclerosis; Biological Transport; Constriction, Pathologic; Drug Delivery Systems; Drug-Eluting Stents; Endothelium, Vascular; Models, Biological; Paclitaxel; Prosthesis Design; Tunica Media; Wound Healing | 2015 |
Impact of Paclitaxel Dose on Tissue Pharmacokinetics and Vascular Healing: A Comparative Drug-Coated Balloon Study in the Familial Hypercholesterolemic Swine Model of Superficial Femoral In-Stent Restenosis.
Topics: Animals; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Disease Models, Animal; Endovascular Procedures; Femoral Artery; Fibrin; Hyperlipoproteinemia Type II; Metals; Neointima; Paclitaxel; Peripheral Arterial Disease; Radiography; Stents; Swine; Tissue Distribution; Vascular Access Devices; Wound Healing | 2015 |
Long-term effectiveness and safety of the sirolimus-eluting BiOSS LIM® dedicated bifurcation stent in the treatment of distal left main stenosis: an international registry.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Constriction, Pathologic; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Prospective Studies; Registries; Sirolimus; Time; Treatment Outcome | 2016 |
Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Chi-Square Distribution; Constriction, Pathologic; Critical Illness; Diabetic Angiopathies; Drug-Eluting Stents; Female; Femoral Artery; Historically Controlled Study; Humans; Ischemia; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Recurrence; Registries; Retreatment; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2016 |
Evaluation of the Biodegradable Igaki-Tamai Scaffold After Drug-Eluting Balloon Treatment of De Novo Superficial Femoral Artery Lesions: The GAIA-DEB Study.
Topics: Absorbable Implants; Aged; Angioplasty, Balloon; Ankle Brachial Index; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Germany; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Pilot Projects; Prospective Studies; Recurrence; Retreatment; Surveys and Questionnaires; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Access Devices; Vascular Patency | 2016 |
Ultrasound triggered image-guided drug delivery to inhibit vascular reconstruction via paclitaxel-loaded microbubbles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Constriction, Pathologic; Drug Compounding; Drug Delivery Systems; Iliac Artery; Microbubbles; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Paclitaxel; Rabbits; Ultrasonic Waves | 2016 |
Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery.
Topics: Aged; Aged, 80 and over; Alloys; Angiography; Angioplasty, Balloon; Area Under Curve; Cardiovascular Agents; Chi-Square Distribution; Constriction, Pathologic; Drug-Eluting Stents; Female; Femoral Artery; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Predictive Value of Tests; Prosthesis Design; Recurrence; Retrospective Studies; Risk Factors; ROC Curve; Stents; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Vascular Patency | 2016 |
Single-Center Experience With Lutonix Drug-Coated Balloons in Infrapopliteal Arteries.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Germany; Humans; Intermittent Claudication; Ischemia; Kaplan-Meier Estimate; Limb Salvage; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2016 |
1-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
Topics: Aged; Angioplasty, Balloon; Ankle Brachial Index; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Female; Femoral Artery; Humans; Italy; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Quality of Life; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Calcification; Vascular Patency | 2016 |
A single center experience of Zilver PTX for femoro-popliteal lesions.
Topics: Aged; Angiography; Angioplasty, Balloon; Cardiovascular Agents; Constriction, Pathologic; District of Columbia; Drug-Eluting Stents; Female; Femoral Artery; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Doppler; Vascular Patency | 2016 |
[Drug coated balloon with paclitaxel for the treatment of symptomatic peripheral artery disease: early and midterm results].
Topics: Aged; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Humans; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Retrospective Studies; Time Factors; Treatment Outcome | 2016 |
Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
Topics: Adult; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Cardiovascular Agents; Constriction, Pathologic; Critical Illness; Disease-Free Survival; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Kaplan-Meier Estimate; Limb Salvage; Male; Metals; Middle Aged; Multivariate Analysis; Paclitaxel; Popliteal Artery; Proportional Hazards Models; Prosthesis Design; Prosthesis Failure; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome; Vascular Patency | 2017 |
Usefulness of paclitaxel-releasing high-pressure balloon associated with cutting balloon angioplasty for treatment of outflow stenoses of failing hemodialysis arteriovenous shunts.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Arteriovenous Shunt, Surgical; Combined Modality Therapy; Constriction, Pathologic; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Renal Dialysis; Treatment Outcome; Vascular Patency | 2017 |
Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Isolated Popliteal Artery Lesions.
Topics: Aged; Aged, 80 and over; Aneurysm; Angiography; Angioplasty, Balloon; Anticoagulants; Atherectomy; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Female; Germany; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Popliteal Artery; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2017 |
Recalcitrant in-stent restenosis of the celiac trunk treated by drug-eluting stent.
Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Cardiovascular Agents; Celiac Artery; Chronic Disease; Constriction, Pathologic; Drug-Eluting Stents; Female; Humans; Ischemia; Magnetic Resonance Angiography; Mesenteric Vascular Occlusion; Metals; Paclitaxel; Prosthesis Design; Recurrence; Stents; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Invited commentary.
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Cardiovascular Agents; Constriction, Pathologic; Critical Illness; Drug-Eluting Stents; Humans; Ischemia; Lower Extremity; Metals; Paclitaxel; Popliteal Artery; Prospective Studies; Prosthesis Design; Secondary Prevention; Stents; Treatment Outcome | 2009 |
Paclitaxel drug-eluting stent placement for pulmonary vein stenosis as a bridge to heart-lung transplantation.
Topics: Assisted Circulation; Constriction, Pathologic; Drug-Eluting Stents; Fatal Outcome; Female; Heart-Lung Transplantation; Humans; Infant; Legionnaires' Disease; Paclitaxel; Pulmonary Veins; Tubulin Modulators | 2009 |
Role of Rho-kinase in the pathogenesis of coronary hyperconstricting responses induced by drug-eluting stents in pigs in vivo.
Topics: Animals; Cells, Cultured; Constriction, Pathologic; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Paclitaxel; rho-Associated Kinases; Swine | 2009 |
Response to drug-eluting stents do we need drugs to recompense drug elution?
Topics: Animals; Constriction, Pathologic; Coronary Artery Disease; Drug-Eluting Stents; Paclitaxel; rho-Associated Kinases; Swine | 2009 |
Drug-eluting tibial stents: objective patency determination.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Arterial Occlusive Diseases; Cardiovascular Agents; Constriction, Pathologic; Drug-Eluting Stents; Female; Humans; Ischemia; Life Tables; Limb Salvage; Male; Middle Aged; Minnesota; Paclitaxel; Platelet Aggregation Inhibitors; Prosthesis Design; Radiography; Recurrence; Reoperation; Retrospective Studies; Severity of Illness Index; Tibial Arteries; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Patency | 2010 |
Drug-eluting stents for the treatment of pulmonary vein stenosis after atrial fibrillation ablation.
Topics: Adult; Aged; Atrial Fibrillation; Catheter Ablation; Constriction, Pathologic; Drug-Eluting Stents; Echocardiography, Transesophageal; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Paclitaxel; Pulmonary Veins; Retrospective Studies; Secondary Prevention; Sirolimus; Treatment Outcome; Vascular Diseases | 2011 |
Seven-year safety and efficacy of the unrestricted use of drug-eluting stents in saphenous vein bypass grafts.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Chi-Square Distribution; Constriction, Pathologic; Coronary Angiography; Coronary Artery Bypass; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Humans; Kaplan-Meier Estimate; Male; Metals; Middle Aged; Myocardial Infarction; Netherlands; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Prosthesis Design; Risk Assessment; Risk Factors; Saphenous Vein; Sirolimus; Stents; Time Factors; Treatment Outcome | 2012 |
Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study.
Topics: Aged; Alloys; Arterial Occlusive Diseases; Canada; Cardiovascular Agents; Constriction, Pathologic; Disease-Free Survival; Drug-Eluting Stents; Endovascular Procedures; Europe; Female; Femoral Artery; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Popliteal Artery; Prospective Studies; Prosthesis Design; Recovery of Function; Recurrence; Republic of Korea; Severity of Illness Index; Time Factors; Treatment Outcome; Vascular Patency | 2011 |
A new paclitaxel-eluting balloon for angioplasty of femoropopliteal obstructions: acute and midterm results.
Topics: Adult; Aged; Aged, 80 and over; Alloys; Angioplasty, Balloon; Ankle Brachial Index; Arterial Occlusive Diseases; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Drug Delivery Systems; Equipment Design; Female; Femoral Artery; Humans; Italy; Male; Middle Aged; Paclitaxel; Popliteal Artery; Prospective Studies; Prosthesis Design; Recurrence; Registries; Stents; Time Factors; Treatment Outcome | 2011 |
Suppression of neointimal hyperplasia by sirolimus-eluting expanded polytetrafluoroethylene (ePTFE) haemodialysis grafts in comparison with paclitaxel-coated grafts.
Topics: Animals; Arteriovenous Shunt, Surgical; Carotid Arteries; Cell Proliferation; Constriction, Pathologic; Female; Graft Occlusion, Vascular; Hyperplasia; Jugular Veins; Models, Animal; Neointima; Paclitaxel; Polytetrafluoroethylene; Renal Dialysis; Sirolimus; Swine; Vascular Grafting | 2012 |
Evaluation of a novel paclitaxel-eluting stent with a bioabsorbable polymeric surface coating in the porcine artery injury model.
Topics: Absorbable Implants; Animals; Constriction, Pathologic; Dioxanes; Disease Models, Animal; Drug-Eluting Stents; Femoral Artery; Microscopy, Electron, Scanning; Paclitaxel; Polymers; Prostheses and Implants; Secondary Prevention; Swine; Tubulin Modulators | 2011 |
Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry.
Topics: Aged; Angioplasty, Balloon; Ankle Brachial Index; Arterial Occlusive Diseases; Cardiovascular Agents; Catheters; Chi-Square Distribution; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Humans; Italy; Kaplan-Meier Estimate; Linear Models; Male; Middle Aged; Paclitaxel; Popliteal Artery; Prospective Studies; Quality of Life; Recovery of Function; Recurrence; Registries; Severity of Illness Index; Time Factors; Treatment Outcome; Vascular Patency; Walking | 2012 |
Use of paclitaxel-eluting balloons for endotherapy of anastomotic strictures following liver transplantation.
Topics: Adult; Anastomosis, Surgical; Cholangiopancreatography, Endoscopic Retrograde; Cholestasis; Cohort Studies; Constriction, Pathologic; Dilatation; Female; Germany; Humans; Liver Transplantation; Male; Middle Aged; Paclitaxel; Postoperative Complications; Prognosis; Prospective Studies; Risk Assessment; Stents; Treatment Outcome | 2012 |
Drug eluting stents: managing coronary artery stenosis following PTCA.
Topics: Angioplasty, Balloon, Coronary; Canada; Clinical Trials as Topic; Constriction, Pathologic; Coronary Disease; Coronary Vessels; Cost-Benefit Analysis; Drug Approval; Drug Delivery Systems; Europe; European Union; Humans; Paclitaxel; Sirolimus; Stents; Treatment Outcome | 2002 |
[A case of advanced gastric cancer showing pylorus stenosis with multiple liver metastases, that respond remarkably to neoadjuvant chemotherapy of combined TXL and low-dose FP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Constriction, Pathologic; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Liver Neoplasms; Male; Paclitaxel; Pylorus; Stomach Neoplasms | 2003 |
[A case of advanced type 4 gastric cancer with peritonitis dissemination, navel metastasis effectively treated with combined chemotherapy of biweekly paclitaxel (TXL) and TS-1].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Colonic Diseases; Constriction, Pathologic; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Pyridines; Splenectomy; Stomach Neoplasms; Tegafur; Umbilicus | 2003 |
Weekly administration of paclitaxel attenuated rectal stenosis caused by multiple peritoneal recurrence 8 years after the resection of gastric carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Constriction, Pathologic; Drug Administration Schedule; Female; Gastrectomy; Humans; Paclitaxel; Peritoneal Neoplasms; Rectal Diseases; Recurrence; Stomach Neoplasms; Time Factors; Treatment Outcome | 2003 |
The effects of paclitaxel on the three phases of restenosis: smooth muscle cell proliferation, migration, and matrix formation: an in vitro study.
Topics: Angioplasty, Balloon; Arteries; Cell Cycle; Cell Division; Cell Movement; Cells, Cultured; Colony-Forming Units Assay; Constriction, Pathologic; Dose-Response Relationship, Drug; Humans; Muscle, Smooth, Vascular; Paclitaxel; Recurrence; Tenascin | 2004 |
Arterial and venous smooth-muscle cells differ in their responses to antiproliferative drugs.
Topics: Arteries; Arteriovenous Shunt, Surgical; Cell Division; Cells, Cultured; Constriction, Pathologic; Dipyridamole; Humans; Muscle, Smooth, Vascular; ortho-Aminobenzoates; Paclitaxel; Renal Dialysis; Veins | 2004 |
[An unresectable advanced gastric cancer with Virchow's metastasis, carcinomatous ascites and rectal stenosis, effectively managed with combined chemotherapy of biweekly paclitaxel and TS-1].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Signet Ring Cell; Constriction, Pathologic; Drug Administration Schedule; Drug Combinations; Female; Humans; Lymphatic Metastasis; Oxonic Acid; Paclitaxel; Peritonitis; Pyridines; Rectal Diseases; Stomach Neoplasms; Tegafur | 2005 |
Colon stenosis in a patient with ulcerative colitis as a manifestation of mixed müllerian tumor of the peritoneum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colitis, Ulcerative; Colon; Constriction, Pathologic; Endoscopy, Gastrointestinal; Female; Humans; Middle Aged; Mixed Tumor, Mullerian; Paclitaxel; Peritoneal Neoplasms | 2005 |
Paclitaxel-eluting stents for the treatment of chronic total coronary occlusions: a strategy of extensive lesion coverage with drug-eluting stents.
Topics: Aged; Antineoplastic Agents, Phytogenic; Chronic Disease; Constriction, Pathologic; Coronary Angiography; Coronary Disease; Coronary Vessels; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Paclitaxel; Prosthesis Design; Retrospective Studies; Stents | 2006 |
Paclitaxel - a tool to prevent stenosis in vascular access for haemodialysis?
Topics: Animals; Arteriovenous Shunt, Surgical; Constriction, Pathologic; Graft Occlusion, Vascular; Humans; Paclitaxel; Renal Dialysis; Swine | 2006 |
[A case of long-term survival of gastric cancer with peritoneal metastasis effectively treated by TS-1 and paclitaxel (PTX) combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Constriction, Pathologic; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Sigmoid Diseases; Stomach Neoplasms; Tegafur | 2006 |
Poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment.
Topics: Animals; Cells, Cultured; Constriction, Pathologic; Drug Delivery Systems; Graft Occlusion, Vascular; Iliac Artery; Lactic Acid; Male; Nanoparticles; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Rabbits | 2007 |
Coating with paclitaxel improves graft survival in a porcine model of haemodialysis graft stenosis.
Topics: Animals; Coated Materials, Biocompatible; Constriction, Pathologic; Disease Models, Animal; Graft Rejection; Graft Survival; Male; Paclitaxel; Polytetrafluoroethylene; Prosthesis Design; Renal Dialysis; Swine; Time Factors; Tubulin Modulators | 2007 |
Reduction of stenosis due to intimal hyperplasia after stent supported angioplasty of peripheral arteries by local administration of paclitaxel in swine.
Topics: Angiography; Angioplasty, Balloon, Coronary; Animals; Constriction, Pathologic; Infusions, Intra-Arterial; Male; Paclitaxel; Peripheral Vascular Diseases; Stents; Swine; Tunica Intima | 2007 |
Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis model.
Topics: Abciximab; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Arteries; Constriction, Pathologic; Coronary Restenosis; Disease Models, Animal; Drug-Eluting Stents; Female; Hyperplasia; Immunoglobulin Fab Fragments; Inflammation; Paclitaxel; Sirolimus; Swine; Tunica Intima | 2007 |
Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Constriction, Pathologic; Paclitaxel; Rabbits; Recurrence; Swine; Vascular Diseases | 2000 |